Cellectis

$33.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-0.48%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can watch Cellectis and buy or sell other stocks, options, and ETFs commission-free!

About CLLS

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France. The listed name for CLLS is Cellectis S.A. American Depositary Shares.

CEO

André Choulika

Employees

264

Headquarters

Paris, Ile-de-France

Founded

1999

Market Cap

1.40B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

488.01K

High Today

$34.71

Low Today

$33.10

Open Price

$33.28

Volume

619.30K

52 Week High

$34.71

52 Week Low

$7.32

Collections

Research And Development

Engineering

Pharmaceutical

Analyst Ratings

86%

of 14 ratings

Buy

86%

Hold

Sell

CLLS Earnings

-$0.80

-$0.34

$0.11

$0.57

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 3, After Hours